These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2046119)

  • 21. Snake oil salesmen or purveyors of knowledge: off-label promotions and the commercial speech doctrine.
    Bagley CE; Mitts J; Tinsley RJ
    Cornell J Law Public Policy; 2013; 23(2):337-93. PubMed ID: 25330567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consumer-directed advertising of contraceptive drugs: the FDA, Depo-Provera, and product liability.
    Green W
    Food Drug Law J; 1995; 50(4):553-67. PubMed ID: 10343019
    [No Abstract]   [Full Text] [Related]  

  • 23. Congress, the FDA, and the fair development of new medications for children.
    McKinney RE
    Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299
    [No Abstract]   [Full Text] [Related]  

  • 24. Forbidden and Permitted Statements about Medications--Loosening the Rules.
    Avorn J; Sarpatwari A; Kesselheim AS
    N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
    [No Abstract]   [Full Text] [Related]  

  • 25. Highlights and a hidden hazard--the FDA's new labeling regulations.
    Avorn J; Shrank W
    N Engl J Med; 2006 Jun; 354(23):2409-11. PubMed ID: 16760439
    [No Abstract]   [Full Text] [Related]  

  • 26. Can speech by FDA-regulated firms ever be noncommercial?
    Cortez N
    Am J Law Med; 2011; 37(2-3):388-421. PubMed ID: 21847886
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 28. Vioxx may go back on sale after scraping past FDA panel.
    Wadman M
    Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
    [No Abstract]   [Full Text] [Related]  

  • 29. Regulatory experts debate FDA's authority.
    Young D
    Am J Health Syst Pharm; 2007 May; 64(9):910, 912. PubMed ID: 17468140
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 31. AHI perspectives: flexible drug labeling and its impact on the drug development process. Liability issues.
    Thomas JW
    J Am Vet Med Assoc; 1995 Oct; 207(7):899-900; discussion 902-4. PubMed ID: 7559021
    [No Abstract]   [Full Text] [Related]  

  • 32. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
    Dorfman HL; Quinn VM; Brophy EA
    Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
    [No Abstract]   [Full Text] [Related]  

  • 33. Trying times for generic medicines in the USA.
    Lancet; 2013 Mar; 381(9872):1072. PubMed ID: 23540840
    [No Abstract]   [Full Text] [Related]  

  • 34. Impossible? Outlawing state safety laws for generic drugs.
    Glantz LH; Annas GJ
    N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
    [No Abstract]   [Full Text] [Related]  

  • 35. Collagen and liquid silicone injections.
    González A
    Bol Asoc Med P R; 1992; 84(4-5):126-7. PubMed ID: 1295499
    [No Abstract]   [Full Text] [Related]  

  • 36. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 37. Warning signs.
    Nature; 2008 Mar; 452(7185):254. PubMed ID: 18354433
    [No Abstract]   [Full Text] [Related]  

  • 38. The Supreme Court, preemption, and malpractice liability.
    Kesselheim AS; Studdert DM
    N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
    [No Abstract]   [Full Text] [Related]  

  • 39. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 40. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
    Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.